Skuldtech is involved in the development of new diagnostics focused on personalized medicine applications. The company has already developed prototypes dedicated to the identification of specific biomarkers.
Due to its expertise in genomics, in gene expression, in New Generation Sequencing (NGS) technologies, in bioinformatics and biostatistics, Skuldtech is currently involved in several developments concerning personalized medicine, companion diagnostics and patient stratification tests, which will enable stratifying and segmenting patients according to “typical profiles.”
Some of these innovative healthcare solutions are being subject to clinical validation.
For instance, Skuldtech has recently patented CMML biomarkers associated to a positive 4 years survival prognosis. These markers have been discovered through Digital Gene Expression analyses realized on several cell lines and blood samples, and have been validated in a clinical trial lead by the Nimes hospital through qRT-PCR technology. These CMML biomarkers will be validated in a large clinical trial in the next months
If you need more information, please contact our business development department
(T: +33(0)467 419 748, Email: firstname.lastname@example.org).
Skuldtech is specialized in the discovery of
new Biomarkers and the development of Diagnostics
focused on personalized medicine applications.
This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics
associated with new treatments, especially in
cancer, neurodegenerative and infectious diseases.